Psoriasis Clinical Trials in Lancaster

View 24 new treatments for Psoriasis in Lancaster, CA, and other areas near me, such as Palmdale. Every day, Power helps hundreds of psoriasis patients connect with leading medical research.
View 29 trials in Lancaster
Filter (29)

Subcutaneous Risankizumab for Psoriasis

AbbVie Clinic, Encino + 2 more

Psoriasis (PsO) is a chronic disease characterized by marked inflammation of the skin that results in thick, red, scaly plaques. This study will assess how safe and effective risankizumab is in adult participants with moderate to severe genital psoriasis or moderate to severe scalp psoriasis. Adverse events and change in disease signs and symptoms will be monitored. Risankizumab (Skyrizi) is a drug being studied for the treatment of moderate to severe genital psoriasis or moderate to severe scalp psoriasis. Approximately 200 participants with moderate to severe genital psoriasis or moderate to severe scalp psoriasis will be enrolled across approximately 45 sites globally. The study will be broken up into 2 sub-studies by disease location, participants with moderate to severe genital psoriasis (Study G) and moderate to severe scalp psoriasis (Study S). In both sub-studies participants will receive subcutaneous (SC) injections of risankizumab during the 52 week treatment period, or SC injections of placebo risankizumab during the 16 week treatment period followed by SC injections of risankizumab during the 36 week treatment period, with an 8-week follow-up period after the 52 week treatment period. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.Show More
Waitlist
Phase 4
Est. 4 - 6 Weeks
ABBVIE INC.
Study Director

COVID-19 VaccinE Response in Rheumatology Patients

Research Clinic, Beverly Hills + 1 more

This trial tests an extra dose of the COVID-19 vaccine in patients with autoimmune diseases. It aims to see if pausing their medications temporarily can make the vaccine more effective. The goal is to improve their immune response to COVID-19.Show More
Recruiting

No Placebo Trial

Phase 4
Est. 3 - 6 Weeks
Jeffrey R Curtis, MD MS MPH
Principal Investigator

Guselkumab for Psoriatic Arthritis

Janssen Clinic, Covina + 1 more

This trial is testing guselkumab, a medication that reduces inflammation, in patients with psoriatic arthritis affecting the spine. It works by blocking a protein called IL-23 to help reduce symptoms and inflammation. Guselkumab is the first IL-23 specific inhibitor approved for the treatment of moderate-to-severe psoriasis.Show More
Recruiting
Phase 4
Est. 3 - 6 Weeks
Janssen Research & Development, LLC Clinical Trial
Study Director

Deucravacitinib for Psoriasis

Bristol-Myers Squibb Clinic, Los Angeles + 1 more

The purpose of this study is to measure the safety and effectiveness of deucravatinib in participants with non-pustular palmoplantar psoriasis and genital psoriasis.Show More
Recruiting
Phase 4
Est. 3 - 12 Weeks
Bristol-Myers Squibb
Study Director

Tildrakizumab for Psoriatic Arthritis

Sun Clinic, Encino + 2 more

This trial is testing tildrakizumab, a medication that reduces inflammation, in patients with active Psoriatic Arthritis who haven't tried certain other treatments. It works by blocking a protein to help manage symptoms. Tildrakizumab is approved for treating moderate to severe plaque psoriasis.Show More
Waitlist
Phase 3
Est. 3 - 12 Weeks
Unregistered Study Lead
Research Team

ESK-001 for Psoriasis

Alumis Clinic, Northridge + 2 more

The goal of this clinical trial is to learn if ESK-001 works to treat moderate to severe plaque psoriasis. The main questions it aims to answer are: * Does ESK-001 reduce the severity of people's psoriasis? * How safe is ESK-001 in people with moderate to severe plaque psoriasis? The study includes 2 comparators: a placebo control (a 'dummy' tablet that does not contain the medicine ESK-001 but looks just like it) and an active control (apremilast, which is a medicine approved to treat psoriasis). People taking part in this study must be men or women aged at least 18 years and have had plaque psoriasis for at least 6 months, currently moderate to severe. Participants will: * take drug every day for 24 weeks. * visit the clinic for checkups and tests. * fill out questionnaires about their psoriasis, itch severity, and change in quality of life. * be assessed for health issues and side effects, physical examinations, vital signs, heart electrical activity measurements, and psychological health. * provide blood and urine samples.Show More
Recruiting
Phase 3
Est. 4 - 6 Weeks
Unregistered Study Lead
Research Team

Risankizumab for Psoriatic Arthritis

AbbVie Clinic, Upland + 1 more

The purpose of this study is to evaluate the safety and efficacy of risankizumab in adults with moderately to severely active psoriatic arthritis (PsA).
Waitlist
Phase 3
Est. 3 - 12 Weeks
AbbVie Inc.
Study Director

Tildrakizumab SC Injection for Psoriatic Arthritis

Sun Clinic, Covina + 1 more

An open label phase 3 study
Waitlist

No Placebo Trial

Phase 3
Est. 4 - 6 Weeks
Unregistered Study Lead
Research Team

Risankizumab for Psoriatic Arthritis

AbbVie Clinic, Upland + 1 more

The purpose of this study is to compare the safety and efficacy of risankizumab versus placebo in participants with moderately to severely active psoriatic arthritis (PsA).Show More
Waitlist
Phase 3
Est. 6 - 12 Weeks
ABBVIE INC.
Study Director

JNJ-77242113 for Plaque Psoriasis

Janssen Clinic, Encino + 3 more

The purpose of the study is to evaluate how effective JNJ-77242113 is in participants with moderate to severe plaque psoriasis compared to placebo and deucravacitinib.Show More
Waitlist
Phase 3
Est. 6 - 12 Weeks
Janssen Research & Development, LLC Clinicaltrial
Study Director
Page 1 of 3

Frequently Asked Questions

How much do psoriasis clinical trials pay?

Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range. Further, most trials will cover the costs of an Uber to-and-from the clinic. Factors that can affect compensation include the phase of the trial, the length of the trial, the frequency of visits, and the specific condition being studied.

Do I need to be insured to participate in a medical study?

Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on Cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

How do psoriasis clinical trials work?

After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll typical be sorted into one of the treatment groups, and will receive your study drug. For some trials, there is a chance you'll receive a placebo. Across psoriasis trials in Lancaster, 42% of clinical trials have a placebo. Typically you'll be required to check-in with the clinic every month or two. The average trial length in this city for psoriasis patients is 6 Months.

What does the "phase" of a clinical trial mean?

The phase of a trial reveals what stage the drug is in getting approval for a specific condition. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. Phase 2 trials are those where the drug has some data showing safety in humans, but where effectiveness has typically only been shown in animals and non-human experiments. Phase 1 trials are the trials where we don't have safety data in humans. As a general rule, phase 3 trials are more promising than phase 2, and phase 2 trials are more promising than phase 1.